ANR.AU · Anatara Lifesciences Limited

-

Please sign in to comment on ANR.AU

1 Comment

Admin

4 years, 5 months ago

Anatara Lifesciences Limited is currently in a long term downtrend where the price is trading 4.9% below its 200 day moving average.

From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.3.

Anatara Lifesciences Limited's total revenue sank by 0.0% to $209K since the same quarter in the previous year.

Its net income has increased by 42.9% to $-1M since the same quarter in the previous year.

Finally, its free cash flow fell by 70.3% to $-948K since the same quarter in the previous year.

Based on the above factors, Anatara Lifesciences Limited gets an overall score of 2/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	AU
CurrencyCode	AUD
ISIN	AU000000ANR0

Market Cap	2M
PE Ratio	None
Target Price	1.79
Beta	0.49
Dividend Yield	None

ABOUT

Anatara Lifesciences Limited

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

ANR.AU · Anatara Lifesciences Limited

-

Anatara Lifesciences Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Anatara Lifesciences Limited using a moving average strategy